A Phase I, Open-Label, Multicenter Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of AZD4635, Both as Monotherapy and in Combination With Durvalumab in Patients With Advanced Solid Malignancies.

Trial Profile

A Phase I, Open-Label, Multicenter Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of AZD4635, Both as Monotherapy and in Combination With Durvalumab in Patients With Advanced Solid Malignancies.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Dec 2017

At a glance

  • Drugs AZD 4635 (Primary) ; Durvalumab (Primary)
  • Indications Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors AstraZeneca
  • Most Recent Events

    • 28 Nov 2017 Planned number of patients changed from 51 to 156.
    • 28 Nov 2017 Planned End Date changed from 9 Nov 2017 to 23 Aug 2019.
    • 28 Nov 2017 Planned primary completion date changed from 9 Nov 2017 to 23 Aug 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top